Guardant Health Engager | Digital Event

Guardant Health

LBx & ctDNA in Endocrine-Resistant Breast Cancer

Tuesday January 25, 2022 |  8:00am PT  |  11:00am ET

LBx & ctDNA in Endocrine-Resistant Breast Cancer

The Guardant Health Engager is an exclusive limited-attendance event that focuses on the impact of disruptive, data-driven, biomarker-based strategies to accelerate drug development and improve cancer patient care. We are inviting high-level executives from BioPharma based in the US and Europe.

Join us to delve into the specific challenges that endocrine-resistant metastatic breast cancer patients are facing and explore the innovative diagnostic solutions to inform treatment decisions.

For instance, our KOL panel will discuss mechanisms of resistance and their associated clinically relevant mutations in advanced breast cancer, as well as the corresponding biomarker-informed treatments. The panelists will also touch on the underlying technological advances, innovative partnership models across drug and diagnostic developers, medical centers, and payors.

Guardant Health will facilitate the KOL panel's forward-looking discussion before opening it up to questions and answers from the audience.

This discussion will highlight thought-provoking biomarker-driven strategies to accelerate clinical trials, extract value from cutting-edge biomarker innovation, and expand therapeutic access for cancer patients.


Cynthia X Ma

Professor of Department of Medicine, Oncology Division

The Genome Institute at Washington University

Fabrice Andre

Director of Research & Professor of Medical Oncology

Institute Gustave Roussy

Iris Faull

Senior Director of Medical Affairs

Guardant Health

Nicholas Turner

ICR Team Leader & Professor of Medical Oncology

Institute of Cancer Research


Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ test for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.


Having trouble registering? Email:

*Attendance is subject to final approval from the event organizers